JP2022509156A5 - - Google Patents
Info
- Publication number
- JP2022509156A5 JP2022509156A5 JP2021528960A JP2021528960A JP2022509156A5 JP 2022509156 A5 JP2022509156 A5 JP 2022509156A5 JP 2021528960 A JP2021528960 A JP 2021528960A JP 2021528960 A JP2021528960 A JP 2021528960A JP 2022509156 A5 JP2022509156 A5 JP 2022509156A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antibody
- variable region
- chain variable
- heavy chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811448228.1 | 2018-11-30 | ||
| CN201811448228 | 2018-11-30 | ||
| PCT/CN2019/121941 WO2020108611A1 (zh) | 2018-11-30 | 2019-11-29 | 抗cd40抗体、其抗原结合片段及其医药用途 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022509156A JP2022509156A (ja) | 2022-01-20 |
| JP2022509156A5 true JP2022509156A5 (cg-RX-API-DMAC7.html) | 2023-02-13 |
Family
ID=70851924
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021528960A Pending JP2022509156A (ja) | 2018-11-30 | 2019-11-29 | 抗cd40抗体、その抗原結合フラグメント、およびその医学的使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20220025060A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3892634A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2022509156A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20210099027A (cg-RX-API-DMAC7.html) |
| CN (1) | CN112969714B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2019389354A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112021009835A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3120793A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2021005823A (cg-RX-API-DMAC7.html) |
| TW (1) | TW202039558A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020108611A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023025194A1 (zh) | 2021-08-24 | 2023-03-02 | 江苏恒瑞医药股份有限公司 | Fap/cd40结合分子及其医药用途 |
| CN119462954B (zh) * | 2022-02-21 | 2025-10-14 | 乐普创一生物科技(上海)有限公司 | 5t4/cd40双特异性抗体 |
| CN114573698B (zh) * | 2022-03-16 | 2023-01-06 | 沈阳三生制药有限责任公司 | 一种FcRn抗原结合蛋白及其制备方法和应用 |
| WO2023186111A1 (zh) * | 2022-04-02 | 2023-10-05 | 和铂医药(上海)有限责任公司 | 一种靶向cd40的抗原结合蛋白及其制备和应用 |
| JP7881232B2 (ja) * | 2022-05-31 | 2026-06-29 | 明済生物製薬(北京)有限公司 | 抗cd40抗体と抗pd-l1×cd40二重特異性抗体及びその使用 |
| CN117229396A (zh) * | 2022-06-06 | 2023-12-15 | 普米斯生物技术(珠海)有限公司 | 抗cd40抗体及其用途 |
| CN117430704B (zh) * | 2022-07-22 | 2026-05-15 | 广东安普泽生物医药股份有限公司 | Cd40抗体或抗原结合片段及其应用 |
| WO2024076969A1 (en) * | 2022-10-04 | 2024-04-11 | Memorial Sloan-Kettering Cancer Center | Anti-cd40 antibodies and uses thereof |
| CN120282801A (zh) | 2022-12-28 | 2025-07-08 | 苏州盛迪亚生物医药有限公司 | 一种cd40结合分子的组合物及医药用途 |
| EP4652203A2 (en) * | 2023-01-18 | 2025-11-26 | Michael Kaleko | Ph-selective antibody-based checkpoint inhibitors for conditional antibody-dependent cellular cytotoxicity |
| KR20250153216A (ko) | 2023-02-24 | 2025-10-24 | 상하이 맙젠 바이오텍 리미티드 | Fap/cd40 결합 분자의 약학적 조성물 및 이의 의약적 용도 |
| TW202436358A (zh) | 2023-03-01 | 2024-09-16 | 大陸商江蘇恆瑞醫藥股份有限公司 | Fap/4-1bb/cd40結合分子及其醫藥用途 |
| CN117924488A (zh) * | 2023-12-13 | 2024-04-26 | 合肥天港免疫药物有限公司 | 阻断性cd40抗体及其应用 |
| CN117756940A (zh) * | 2023-12-22 | 2024-03-26 | 深圳市英特立捷生物科技有限公司 | 一种靶向人cd40的单克隆抗体及其应用 |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH10308991A (ja) | 1997-05-07 | 1998-11-17 | Mitsubishi Electric Corp | スピーカー取付構造 |
| US6946129B1 (en) | 1999-06-08 | 2005-09-20 | Seattle Genetics, Inc. | Recombinant anti-CD40 antibody and uses thereof |
| US20030059427A1 (en) | 2000-04-28 | 2003-03-27 | Force Walker R. | Isolation and characterization of highly active anti-CD40 antibody |
| WO2002028481A2 (en) | 2000-10-02 | 2002-04-11 | Chiron Corporation | Methods of therapy for b-cell malignancies using antagonist anti-cd40 antibodies |
| CA2658221C (en) * | 2001-04-27 | 2012-11-27 | Kyowa Kirin Co., Ltd. | Anti-cd40 monoclonal antibody |
| AR039067A1 (es) | 2001-11-09 | 2005-02-09 | Pfizer Prod Inc | Anticuerpos para cd40 |
| US20040132101A1 (en) * | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
| US7317091B2 (en) | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
| US8084582B2 (en) | 2003-03-03 | 2011-12-27 | Xencor, Inc. | Optimized anti-CD20 monoclonal antibodies having Fc variants |
| US20090010920A1 (en) | 2003-03-03 | 2009-01-08 | Xencor, Inc. | Fc Variants Having Decreased Affinity for FcyRIIb |
| EP1707627B1 (en) * | 2003-12-25 | 2012-11-14 | Kyowa Hakko Kirin Co., Ltd. | Antagonistic anti-CD40 antibody mutant |
| US20070292439A1 (en) * | 2004-04-27 | 2007-12-20 | Novartis Vaccines And Diagnostics, Inc. | Antagonist Anti-Cd40 Monoclonal Antibodies and Methods for Their Use |
| RU2006141632A (ru) | 2004-04-27 | 2008-06-10 | Новартис Вэксинес Энд Дайэгностикс, Инк. (Us) | Антагонистические моноклональные анти-cd40-антитела и способы их применения |
| EP3342782B1 (en) | 2004-07-15 | 2022-08-17 | Xencor, Inc. | Optimized fc variants |
| JP5027804B2 (ja) | 2005-05-26 | 2012-09-19 | シアトル ジェネティクス,インコーポレーテッド | ヒト化抗cd40抗体およびその使用方法 |
| EP1854810A1 (en) | 2006-05-09 | 2007-11-14 | PanGenetics B.V. | Deimmunized antagonistic anti-human CD40 monoclonal antibody from the ch5D12 antibody |
| CA2693053C (en) | 2007-05-30 | 2021-01-05 | Xencor, Inc. | Methods and compositions for inhibiting cd32b expressing cells |
| EP2796467B1 (en) | 2010-03-31 | 2018-03-28 | Boehringer Ingelheim International GmbH | Anti-CD40 antibodies |
| US20120114652A1 (en) * | 2010-05-03 | 2012-05-10 | Abbott Laboratories | Anti-pai-1 antibodies and methods of use thereof |
| NO2699601T3 (cg-RX-API-DMAC7.html) | 2011-04-21 | 2018-06-16 | ||
| KR102037432B1 (ko) * | 2011-04-29 | 2019-11-27 | 아펙시젠, 인코포레이티드 | 항-cd40 항체 및 사용 방법 |
| GB201115280D0 (en) | 2011-09-05 | 2011-10-19 | Alligator Bioscience Ab | Antibodies, uses and methods |
| CA2888763A1 (en) | 2012-10-30 | 2014-05-08 | Apexigen, Inc. | Anti-cd40 antibodies and methods of use |
| EP3587448B1 (en) | 2013-03-15 | 2021-05-19 | Xencor, Inc. | Heterodimeric proteins |
| WO2015009853A1 (en) | 2013-07-16 | 2015-01-22 | University Of Louisville Research Foundation, Inc. | Compositions for mucusal delivery, useful for treating papillomavirus infections |
| GB201322583D0 (en) * | 2013-12-19 | 2014-02-05 | Alligator Bioscience Ab | Antibodies |
| EP3180087B1 (en) * | 2014-08-12 | 2019-03-13 | Alligator Bioscience AB | Combination therapies with anti cd40 antibodies |
| CA2980460A1 (en) * | 2015-04-13 | 2016-10-20 | Five Prime Therapeutics, Inc. | Combination therapy for cancer |
| JP6518917B2 (ja) | 2015-05-29 | 2019-05-29 | アッヴィ・インコーポレイテッド | 抗cd40抗体およびその使用 |
| PE20180315A1 (es) * | 2015-06-29 | 2018-02-09 | Bristol Myers Squibb Co | Anticuerpos para cd40 |
| MX2017016502A (es) * | 2015-06-29 | 2018-03-12 | Univ Rockefeller | Anticuerpos contra cd40 con actividad agonista mejorada. |
| WO2017040932A1 (en) | 2015-09-04 | 2017-03-09 | Primatope Therapeutics Inc. | Humanized anti-cd40 antibodies and uses thereof |
| CN106957366B (zh) * | 2016-01-12 | 2022-02-01 | 上海昀怡健康科技发展有限公司 | 一种C5aR抗体及其制备方法和应用 |
| SMT202100721T1 (it) * | 2016-05-27 | 2022-01-10 | Abbvie Biotherapeutics Inc | Anticorpi anti-cd40 e loro usi |
| JP7573365B2 (ja) * | 2016-08-12 | 2024-10-25 | メルク パテント ゲーエムベーハー | 癌の併用療法 |
| KR20190133233A (ko) * | 2017-03-30 | 2019-12-02 | 지앙수 헨그루이 메디슨 컴퍼니 리미티드 | 항체-약물 접합체를 제조하는 방법 |
| MX2019014375A (es) * | 2017-06-01 | 2020-01-23 | Jiangsu Hengrui Medicine Co | Anticuerpo anti-cd40, fragmento de union a antigeno del mismo, y uso medico del mismo. |
-
2019
- 2019-11-29 MX MX2021005823A patent/MX2021005823A/es unknown
- 2019-11-29 US US17/296,519 patent/US20220025060A1/en not_active Abandoned
- 2019-11-29 BR BR112021009835-6A patent/BR112021009835A2/pt not_active IP Right Cessation
- 2019-11-29 CA CA3120793A patent/CA3120793A1/en active Pending
- 2019-11-29 CN CN201980072271.9A patent/CN112969714B/zh active Active
- 2019-11-29 KR KR1020217019296A patent/KR20210099027A/ko not_active Ceased
- 2019-11-29 JP JP2021528960A patent/JP2022509156A/ja active Pending
- 2019-11-29 TW TW108143719A patent/TW202039558A/zh unknown
- 2019-11-29 WO PCT/CN2019/121941 patent/WO2020108611A1/zh not_active Ceased
- 2019-11-29 AU AU2019389354A patent/AU2019389354A1/en not_active Abandoned
- 2019-11-29 EP EP19891086.1A patent/EP3892634A4/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110352200B (zh) | 抗具有Ig和ITIM结构域的T细胞免疫受体(TIGIT)的抗体及其应用 | |
| CN112969714B (zh) | 抗cd40抗体、其抗原结合片段及其医药用途 | |
| RU2739617C2 (ru) | Конъюгаты антитело-лекарственное средство (adc), которые связываются с белками flt3 | |
| RU2018119165A (ru) | Антитело против лиганда 1 запрограммированной гибели клеток (pd-l1), его антигенсвязывающий фрагмент и их медицинское применение | |
| US20200347130A1 (en) | CD96 Antibody, Antigen-Binding Fragment and Pharmaceutical use Thereof | |
| RU2018145852A (ru) | Антитело против lag-3, его антигенсвязывающий фрагмент и их фармацевтическое применение | |
| RU2019141289A (ru) | АНТИ-SIRPα АНТИТЕЛА | |
| BR112021005868A2 (pt) | Anticorpos anti-hla-g, composições compreendendo anticorpos anti-hla-g e métodos de uso de anticorpos anti-hla-g | |
| US11851460B2 (en) | PD1 binding agents | |
| KR20190117493A (ko) | 항 pd-1 항체 및 그의 용도 | |
| RU2020127196A (ru) | Антитело против 4-1bb, его антигенсвязывающий фрагмент и его медицинское применение | |
| JP2017149720A5 (cg-RX-API-DMAC7.html) | ||
| JP2012509881A5 (cg-RX-API-DMAC7.html) | ||
| JP2022533538A5 (cg-RX-API-DMAC7.html) | ||
| TW201041592A (en) | Anti-TNF-α antibodies and their uses | |
| CN112513094A (zh) | 结合人her2的抗体、其制备方法和用途 | |
| JP2015503909A5 (cg-RX-API-DMAC7.html) | ||
| JP2012532851A5 (cg-RX-API-DMAC7.html) | ||
| JP2014524902A5 (cg-RX-API-DMAC7.html) | ||
| AU2016334290B2 (en) | Antibody to hepatitis B surface antigen and use thereof | |
| JP2020521504A (ja) | 抗cd40抗体、その抗原結合フラグメント、およびその医学的使用 | |
| US20250179195A1 (en) | Anti-flt3 antibodies and compositions | |
| CN116059341A (zh) | 药物组合物及用途 | |
| KR20230117183A (ko) | 새로운 종양 인게이저 치료 약물의 개발 및 이의 용도 | |
| CA3256036A1 (en) | Anti-PVRIG antibodies, pharmaceutical composition and associated uses |